Ezetimibe or PCSK9 inhibitor with maximally tolerated statin therapy in people with diabetes, LDL-C of ≥70 mg/dL (≥1.8 mmol/L), and ASCVD risk, aged 40-75 years. This evidence concerns the gene PCSK9 and diabetes mellitus.